Newsroom | 23347 results

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2026 results on Tuesday, July 28, 2026, after the close of the market. Acadia will host a conference call with institutional investors and analysts on Wednesday, July 29, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website, and the archived webcast will be availabl...

MIAMI & BOSTON--(BUSINESS WIRE)--OpenEvidence and the Anticoagulation Forum (AC Forum) today announced a strategic partnership to provide antithrombotic guidance and tools that support decision-making in clinical practice. By combining the AC Forum’s leadership in education and multidisciplinary clinical guidance with OpenEvidence’s advanced artificial intelligence platform, clinicians will gain access to timely and practical evidence in antithrombotic therapy. “Clinicians are increasingly turn...

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Eradivir, Inc., a clinical-stage biotech company developing antibody-recruiting small molecules to treat disease, today announced the dosing of the first patient with influenza in a Phase 2 study evaluating EV25 in adults with naturally occurring influenza infection in Bangladesh. The safety lead-in portion of the study was completed last month, with EV25 being well tolerated across all cohorts. The study marks the first evaluation of EV25 in patients with...

BALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems (Real Time), the industry-leading, KLAS Rated, and HITRUST r2 Certified post-acute care analytics solution, announced today that its Real Time Portal has achieved System and Organization Controls (SOC) 2 Type 2 compliance, demonstrating its ability to securely manage customer data and maintain strong, reliable safeguards over time. Conducted in accordance with the standards of the American Institute of Certified Public Accountants (AICPA), t...

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the treatment of atopic dermatitis. The multi-week review resulted in the final Stage 2 study design, incorporating data-driven refinements to patient selection, dise...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcastle disease (ND) and Marek’s disease viruses. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both diseases with a single dose. Newcastle disease is a notifiable disease under EU anim...

SAN DIEGO--(BUSINESS WIRE)--Another record setting quarter reflects accelerating hospital adoption of solutions that support standardized blood culture collection....

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (« MindWalk ») (NASDAQ : HYFT), société spécialisée dans l'intelligence artificielle bio-native, a annoncé aujourd'hui son intégration à l'indice Russell 3000E, après la clôture des marchés des États-Unis le 26 juin 2026, dans le cadre de la reconstitution semestrielle des indices Russell américains de FTSE Russell en juin 2026. Cette intégration a été confirmée dans les données de l'indice publiées le 29 juin 2026. L'indice Russell 3000E...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced that it has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, as part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was reconfirmed in index data published June 29, 2026. The Russell 3000E Index is FTSE Russell's broadest measure of the U.S. equity market, covering up to the 4,000 of t...

SAN JOSE, Calif.--(BUSINESS WIRE)--Visby Medical, the at-home diagnostics company, today announced U.S. Food and Drug Administration (FDA) clearance for the Visby Medical Flu and COVID-19 Test, the first multi-viral at-home PCR test. This marks Visby’s second over-the-counter PCR test and expands the company’s growing portfolio of rapid molecular diagnostics designed for home use. The clearance comes as demand for at-home testing continues to grow, particularly for respiratory infections like C...